** Shares of Emergent BioSolutions EBS.N rise 20.1% to $11.05 premarket
** Late on Wednesday, drugmaker raised the lower end of its annual rev. forecast to $1.07 bln from $1.05, while keeping upper end at $1.13 bln
** It also expects a narrower loss of $30 mln to $50 mln for 2024 versus its earlier estimate of $75 mln to $115 mln
** Co's Q3 adj. EPS of $1.37 beat Wall Street estimates of 14 cents - LSEG
** However, EBS' Q3 rev. of $293.8 mln missed estimates of $297.5 mln
** Co also said its smallpox drug Tembexa was included in a clinical trial for mpox led by the Africa Centres for Disease Control and Prevention
** Up to last close, stock has almost quadrupled YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。